A gap in scientific knowledge about a family of drugs that are used to treat Type 2 diabetes has been highlighted in a new study. Researchers behind the study say that while their results are speculative at this stage, they point to a lack of complete information about the potential impact of a group of treatments known as GLP-1 agonists, or incretin mimetics.

Research has found evidence that spending time in nature provides protections against a startling range of diseases, including depression, diabetes, obesity, ADHD, cardiovascular disease, cancer, and many more. How this exposure to green space leads to better health has remained a mystery.

Two recently published studies in the journals Age and the British Journal of Nutrition (BJN) demonstrate that consuming cocoa flavanols improves cardiovascular function and lessens the burden on the heart that comes with the ageing and stiffening of arteries. The studies also provide novel data to indicate that intake of cocoa flavanols reduces the risk of developing cardiovascular disease (CVD).

Eating a Mediterranean diet supplemented with extra virgin olive oil was associated with a relatively lower risk of breast cancer in a study of women in Spain, according to an article published online by JAMA Internal Medicine. Breast cancer is a frequently diagnosed cancer and a leading cause of death in women.

Capsaicin, the compound responsible for chilis' heat, is used in creams sold to relieve pain, and recent research shows that in high doses, it kills prostate cancer cells. Now researchers are finding clues that help explain how the substance works. Their conclusions suggest that one day it could come in a new, therapeutic form.

Sticky resin from conifers contains substances that could relieve or cure epilepsy. Researchers at Linköping University have synthesized and tested 71 substances known as resin acids, of which twelve are prime candidates for new medicines.

Eight of 14 patients in the first trial of the University of Pennsylvania’s personalized cellular therapy for chronic lymphocytic leukemia (CLL) responded to the therapy, with some complete remissions continuing past four and a half years. These results, published in Science Translational Medicine, represent the most mature data from clinical trials of an approach known as CTL019, developed by a team from Penn's Abramson Cancer Center and the Perelman School of Medicine.